HK Stock MarketDetailed Quotes

02552 HUA MEDICINE-B

Watchlist
  • 1.410
  • +0.010+0.71%
Noon Break Dec 5 11:28 CST
1.49BMarket Cap-5164P/E (TTM)

About HUA MEDICINE-B Company

Hualing Pharmaceutical is a Chinese drug development company currently working to develop the world's first innovative oral drug, Dorzagliatin, or HMS5552, for the treatment of type 2 diabetes. Dorzagliatin is a glucokinase activator, or GKA, designed to control the progressive degenerative properties of diabetes by restoring glucose homeostatic balance in type 2 diabetics. By addressing the glucose-sensing function of glucokinase (or GK), we believe Dorzagliatin may become the first-line standard treatment for type 2 diabetes, either as a monotherapy or as basic treatment in combination with currently approved antidiabetic drugs. Our phase I and phase II clinical trials showed a proof of concept. Participants clinically showed significant reductions in blood sugar and glycated hemoglobin (or Hb1Ac) levels when beta cell function in the pancreas was enhanced and insulin resistance decreased. A 12-week trial of 258 patients with type 2 diabetes in China showed that Dorzagliatin reduced HbA1c by 1.12% in the 75-mg group twice daily; we used the same dose in the phase III clinical trial. In this group, 44.9% of patients had blood sugar controlled (HbA1c levels measured below 7.0% at week 12), and 75.0% of patients had HbA1c drop by 10% or more from baseline levels at week 12. Additionally, 35.4% of patients reached the composite end point based on the following three clinical endpoints: (i) glycemic control with HbA1c levels below 7.0%; (ii) no weight gain; and (iii) no hypoglycemia (dangerously low blood sugar levels). The results of the phase II clinical trial demonstrated the effect of restoring glucose homeostasis. Even when Dorzagliatin was given for only 12 weeks, a relatively high percentage (35.4%) of patients reached the composite end point, and a relatively high percentage (75.0%) of patients had HbA1c levels reduced by more than 10% from baseline. Coupled with improved beta cell function and reduced insulin resistance that continued to work at the end of week 13 (one week after the end of phase II clinical trials), these results showed a significant improvement compared to currently available antidiabetic drugs, and showed differentiated efficacy in improving the course of the disease.

Company Profile

Symbol02552
Company NameHUA MEDICINE-B
ISINKYG4644K1022
Listing DateSep 14, 2018
Issue Price8.28
Shares Offered104.76M share(s)
FoundedNov 10, 2009
Registered AddressCayman Islands
ChairmanRobert Taylor NELSEN
Secretaryyingxin yuan
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands
Head Office and Principal Place of BusinessRoom 506, Hang Seng Wanchai Building, 200 Hennessy Road, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees172
MarketHong Kong motherboard
Phone+86 21 3810 1800
Fax+86 21 3810 1808
EmailBD@huamedicine.com
Business Hualing Pharmaceutical is a Chinese company mainly engaged in drug development business. The company is currently working on developing a new oral drug, Dorzagliatin or HMS5552, for the treatment of type 2 diabetes. The company mainly operates in domestic and foreign markets.

Company Executives

  • Name
  • Position
  • Salary
  • li chen
  • CEO, Executive Director, Chairman of the Strategy Committee, Founder
  • 17.08M
  • jiecheng lin
  • Executive Vice President, Executive Director, Chief Strategy Officer, Strategy Committee Members, Authorized Representative
  • 7.16M
  • yi zhang
  • Executive Director, Senior Vice President (Clinical Research and Development)
  • --
  • Robert Taylor NELSEN
  • Chairman of the Board, Non-executive Directors, Chairman of the Nomination Committee, Strategy Committee Members
  • --
  • Fangxin LI
  • Non-executive Directors, Remuneration Committee Members
  • --
  • William Robert KELLER
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
  • 540.00K
  • yaohua xu
  • Independent Non-Executive Director, Remuneration Committee Members, Audit Committee Members, Nomination Committee Members
  • 450.00K
  • yaoliang zhang
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • 540.00K
  • jin she
  • Senior Vice President and Chief Manufacturing Officer of Pharmaceutical Production and Quality Control
  • --
  • fuxing tang
  • Chief Technology Officer, Vice President of Pharmaceutical Production and Quality Control and Head of US R&D
  • --
  • ying xie
  • Vice President of Quality Assurance, Chief Quality Officer
  • --
  • qing dong
  • Vice President of Pharmaceutical Commercialization
  • --
  • zhanghong li
  • CEO of Nanjing Shengdreier Pharmaceutical Technology Co., Ltd., Group Chief Scientific Officer
  • --
  • yingxin yuan
  • Authorized Representative, Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data